YIF1B

Across TCGA pan-cancer cohorts, YIF1B mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated YIF1B data layer compared with 24 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher YIF1B mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated YIF1B expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

LUAD, PDAC, and CCRCC are the cancer types where YIF1B mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Quartile	All	0.670	0.934	.001	41	view →
PDAC	OS	Median	All	0.242	0.698	.004	22	view →
CCRCC	DFS	Median	III,IV	0.232	0.677	.013	9	view →
UCEC	OS	Median	II,III,IV	1.000	0.620	.011	8	view →
LSCC	DFS	Quartile	III,IV	0.229	0.867	.015	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

YIF1B–LUAD (OS)

Open the LUAD breakdown →